Enliven Therapeutics, Inc. (ELVN)
(Real Time Quote from BATS)
$18.91 USD
-0.31 (-1.61%)
Updated Aug 6, 2025 03:50 PM ET
2-Buy of 5 2
F Value F Growth D Momentum F VGM
Fundamental Charts
About PEG Ratio (TTM)
The company's trailing twelve month (TTM) PEG ratio is the P/E ratio divided by its long-term growth rate consensus. This ratio essentially compares the P/E to its growth rate, thus, for many, telling a more complete story than just the P/E ratio alone. Conventional wisdom says that a PEG ratio of 1 or less is considered good (at par or undervalued to its growth rate). A value greater than 1, in general, is not as good (overvalued to its growth rate). For example, a company with a P/E ratio of 25 and a growth rate of 20% would have a PEG ratio of 1.25 (25 / 20 = 1.25). A company with a P/E ratio of 40 and a growth rate of 50% would have a PEG ratio of 0.80 (40 / 50 = 0.80). Traditionally, investors would look at the stock with the lower P/E and deem it a bargain. But when compared to its growth rate, it doesn't have the earnings growth to justify its P/E. In this example, the one with the P/E of 40 is the better bargain because it is selling at a discount to its growth rate. So the PEG ratio tells you what you're paying for each unit of earnings growth.
ELVN 18.91 -0.31(-1.61%)
Will ELVN be a Portfolio Killer in August?
Zacks Investment Research is releasing its prediction for ELVN based on the 1-3 month trading system that more than doubles the S&P 500.
Zacks News for ELVN
Can Enliven Therapeutics, Inc. (ELVN) Climb 75.66% to Reach the Level Wall Street Analysts Expect?
Enliven Therapeutics, Inc. (ELVN) Is a Great Choice for 'Trend' Investors, Here's Why
ELVN: What are Zacks experts saying now?
Zacks Private Portfolio Services
Here's Why Momentum in Enliven Therapeutics, Inc. (ELVN) Should Keep going
Wall Street Analysts See a 58.78% Upside in Enliven Therapeutics, Inc. (ELVN): Can the Stock Really Move This High?
Wall Street Analysts Think Enliven Therapeutics, Inc. (ELVN) Could Surge 43.04%: Read This Before Placing a Bet
Other News for ELVN
BlackRock, Inc. Reduces Stake in Enliven Therapeutics Inc.
Enliven Therapeutics Inc Breaks Above 200-Day Moving Average - Bullish for ELVN
COMMODORE CAPITAL LP Acquires 1,175,000 Shares in Cidara Therapeutics Inc
Meta To Rally Around 3%? Here Are 10 Top Analyst Forecasts For Wednesday
Enliven Therapeutics (ELVN) Receives Raised Price Target from HC Wainwright & Co. ...